[시장보고서]마이크로바이옴 진단 시장 규모, 점유율 및 동향 분석 보고서 - 용도별, 제품별, 샘플별, 기술별, 최종 사용자별, 지역별 전망 및 예측(2023-2030년)

마이크로바이옴 진단 시장 규모, 점유율 및 동향 분석 보고서 - 용도별, 제품별, 샘플별, 기술별, 최종 사용자별, 지역별 전망 및 예측(2023-2030년)

Global Microbiome Diagnostics Market Size, Share & Trends Analysis Report By Application, By Product, By Sample, By Technology, By End User, By Regional Outlook and Forecast, 2023 - 2030

상품코드 : 1462010 해당 상품은 즉시 배송 가능합니다

리서치사 : KBV Research

발행일 : 2024년 03월

페이지 정보 : 영문 358 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,600

￦ 5,341,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320

￦ 6,409,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048

￦ 8,973,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

마이크로바이옴 진단 시장 규모는 예측 기간 동안 17.5%의 연평균 복합 성장률(CAGR)로 성장하여 2030년까지 4억 1,610만 달러에 달할 것으로 예상됩니다.

또한, 특히 차세대 염기서열 분석(NGS) 기술의 발전으로 마이크로바이옴 분석의 정확도와 해상도가 향상되고 있습니다. 개선된 시퀀싱 플랫폼과 알고리즘은 희귀한 미생물 분류군이나 미생물 군집 구성의 미묘한 변화를 감지할 수 있어 마이크로바이옴 검사의 진단 정확도를 향상시킬 수 있습니다. 따라서 마이크로바이옴 진단의 지속적인 기술 발전이 시장 성장을 견인할 것입니다.

또한, 코로나19 팬데믹은 마이크로바이옴 진단을 포함한 다양한 분야의 연구 활동과 임상시험에 혼란을 초래했습니다. 많은 연구 프로젝트와 임상 연구는 실험실 접근 제한, 자금 삭감, 코로나19 연구 활동의 우선순위 지정으로 인해 지연, 중단 또는 취소되었습니다. 일부 기업들은 이 분야에 대한 관심이 높아지면서 새로운 진단 솔루션에 대한 수요를 충족시키기 위해 마이크로바이옴 진단 분야로 진출했습니다. 이처럼 코로나19 팬데믹은 시장에 적당한 영향을 미쳤습니다.

그러나 인간 숙주와 미생물군집의 상호작용은 매우 복잡하고 역동적이며, 유전, 식습관, 생활습관, 환경, 면역기능 등 다양한 요인에 의해 영향을 받습니다. 미생물 군집과 숙주의 생리적 기능, 대사 및 면역 반응과의 복잡한 관계를 이해하는 것은 어렵습니다. 따라서 미생물 군집과 숙주의 상호 작용에 대한 이해가 제한적이어서 시장 성장을 저해하고 있습니다.

북미
- 북미 시장 : 국가별
  - 미국
  - 캐나다
  - 멕시코
  - 기타 북미
유럽
- 유럽 시장 : 국가별
  - 독일
  - 영국
  - 프랑스
  - 러시아
  - 스페인
  - 이탈리아
  - 기타 유럽
아시아태평양
- 아시아태평양 시장 : 국가별
  - 중국
  - 일본
  - 인도
  - 한국
  - 호주
  - 말레이시아
  - 기타 아시아태평양
라틴아메리카/중동 및 아프리카
- 라틴아메리카/중동 및 아프리카 시장 : 국가별
  - 브라질
  - 아르헨티나
  - 아랍에미리트(UAE)
  - 사우디아라비아
  - 남아프리카공화국
  - 나이지리아
  - 기타 라틴아메리카/중동 및 아프리카

제11장 기업 개요

Illumina, Inc
Becton, Dickinson, and Company
Genetic Analysis AS
Microba Life Sciences Limited
BioMe Oxford Ltd
Viome Life Sciences, Inc
GoodGut SL.U.(HIPRA, S.A.)
Sun Genomics
Origin Sciences Limited
Decode Age

제12장 마이크로바이옴 진단 시장을 위한 성공 필수 조건

LSH

영문 목차

영문목차

The Global Microbiome Diagnostics Market size is expected to reach $416.1 million by 2030, rising at a market growth of 17.5% CAGR during the forecast period.

Microbiome diagnostics offer a complementary approach to traditional diagnostic modalities by providing insights into the gut microbiome's role in metabolic health, facilitating early detection of metabolic disturbances, and stratifying individuals based on their metabolic risk profiles. Thus, the metabolic diseases segment acquired $16,399.8 thousand revenue in 2022. Metabolic diseases pose diagnostic challenges due to their multifactorial nature, heterogeneous presentation, and overlapping symptoms.

Microbiome diagnostics have applications across many healthcare areas beyond traditional fields like gastroenterology. As research progresses, the microbiome's influence on various aspects of human health becomes increasingly apparent. It enables clinicians to develop personalized interventions, such as targeted probiotics, prebiotics, or dietary modifications, to optimize patient health outcomes.

Additionally, Technological advancements, particularly in next-generation sequencing (NGS) technologies, enable higher precision and resolution in microbiome analysis. Improved sequencing platforms and algorithms allow for detecting rare microbial taxa and subtle changes in microbial community composition, enhancing the diagnostic accuracy of microbiome tests. Hence, ongoing technological advancements in microbiome diagnostics drive the market's growth.

Further, the COVID-19 pandemic disrupted research activities and clinical trials across various fields, including microbiome diagnostics. Many research projects and clinical studies were delayed, suspended, or canceled due to restrictions on laboratory access, reduced funding, and prioritization of COVID-19 research efforts. Some companies expanded into microbiome diagnostics to capitalize on the growing interest in this field and to meet the demand for novel diagnostic solutions. Thus, the COVID-19 pandemic moderately impacted the market.

However, the interactions between the human host and the microbiome are highly complex and dynamic, influenced by numerous factors such as genetics, diet, lifestyle, environment, and immune function. Understanding the intricate relationships between microbial communities and host physiology, metabolism, and immune responses is challenging. Thus, a limited understanding of microbiome-host interactions hampers the market's growth.

By Application Analysis

By application, the market is divided into disease diagnostics and research application. In 2022, the disease diagnostics segment registered the largest 52.2% share in the market. It enables a precision medicine approach to disease diagnosis by assessing individual microbial profiles and their associations with specific health conditions.

By Disease Diagnostics Analysis

The disease diagnostics segment is subdivided into gastrointestinal disorders, metabolic diseases, and others. In 2022, the gastrointestinal disorders segment attained a 49% share in the microbiome diagnostics market. Gastrointestinal disorders, including inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), and colorectal cancer, affect millions of people worldwide.

By Product Analysis

Based on product, the market is bifurcated into reagents & kits and instruments. The instruments segment attained a substantial 37.2% revenue share in the market in 2022. Technological advancements have led to the development of sophisticated instruments tailored for microbiome analysis.

By Sample Analysis

Based on sample, the market is categorized into fecal, saliva, skin, and others. In 2022, the fecal segment registered the highest 51.4% revenue share in the market. Fecal samples are a rich source of microbial diversity, containing diverse bacteria, fungi, viruses, and other microorganisms inhabiting the gastrointestinal tract.

By Technology Analysis

On the basis of technology, the market is segmented into 16S rRNA sequencing, shot gun metagenomics, metatranscriptomics, and others. In 2022, the shot gun metagenomics segment attained a 21.4% revenue share in the market.

By End User Analysis

Based on end user, the market is divided into hospitals, academic & research institutes, and biotechnology & pharmaceutical companies. The hospitals segment attained a 49% revenue share in the market in 2022. Hospitals are primary centers for diagnosing and treating various medical conditions, including infectious diseases, chronic illnesses, and complex disorders.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed a 51% revenue share in the market in 2022. There has been increasing recognition of the microbiome's role in human health and disease among healthcare professionals, researchers, and the general population in North America.

Recent Strategies Deployed in the Market

Dec-2023: Genetic Analysis AS collaborated with Comono AS, an IT service and IT consulting firm. Under this collaboration, Genetic Analysis AS would evolve a digital line of work platform for the consumer market for testing of microbiome. Moreover, Genetic Analysis AS would enter into the microbiome consumer testing market to offer distinctive and accessible testing services.
Nov-2023: Viome Life Sciences acquired Naring Health, a high-tech health and wellness firm. Through this acquisition, Viome Life Sciences would enable its user's accurate insight into their biochemical identity.
May-2023: Microba Life Sciences collaborated with Mainz Biomed N.V., a Germany-based molecular diagnostic company. Under this collaboration, both companies would accelerate the development of the PancAlert project by using bioinformatic tools and a metagenomic sequencing mechanism to locate microbiome biomarkers for the detection of pancreatic cancer.
Mar-2023: Becton, Dickinson, and Company received FDA approval for a Vaginal Panel, an extensive diagnostic test that identifies causes of vaginitis. The BD COR system allows STI testing and critical health of women by strengthening patient management and laboratory operations with the latest molecular diagnostic features.
Mar-2023: Microba Life Sciences unveiled MetaXplore, a series of testing products such as MetaXplore GI and MetaXplore GI Plus. With the launch of MetaXplore, Microba would be able to provide healthcare professionals with new technology products for diagnosing gastrointestinal health and analysis of metagenomic-operated gut microbiota.
Jul-2022: Viome Life Sciences launched the Full Body Intelligence Test, an advanced comprehensive health and microbiome-based test. With the launch of this product oral and gut microbiome tests would be done at homes. Additionally, the product would also identify the root causes of cancer, aging, and chronic diseases.

List of Key Companies Profiled

Illumina, Inc.
Becton, Dickinson and Company
Genetic Analysis AS
Microba Life Sciences Limited
BioMe Oxford Ltd
Viome Life Sciences, Inc.
GoodGut S.L.U. (HIPRA, S.A.)
Sun Genomics
Origin Sciences Limited
Decode Age

Global Microbiome Diagnostics Market Report Segmentation

By Application

Disease Diagnostics
- Gastrointestinal Disorders
- Metabolic Diseases
- Others
Research Application

By Product

Reagents & Kits
Instruments

By Sample

Fecal
Saliva
Skin
Others

By Technology

16S rRNA Sequencing
Shot Gun Metagenomics
Metatranscriptomics
Others

By End User

Hospitals
Academic & Research Institutes
Biotechnology & Pharmaceutical Companies

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1Global Microbiome Diagnostics Market, by Application
- 1.4.2Global Microbiome Diagnostics Market, by Product
- 1.4.3Global Microbiome Diagnostics Market, by Sample
- 1.4.4Global Microbiome Diagnostics Market, by Technology
- 1.4.5Global Microbiome Diagnostics Market, by End User
- 1.4.6Global Microbiome Diagnostics Market, by Geography
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Opportunities
- 3.2.3Market Restraints
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.Strategies Deployed in Microbiome Diagnostics Market

Chapter 5.Global Microbiome Diagnostics Market by Application

5.1Global Disease Diagnostics Market by Region
5.2Global Microbiome Diagnostics Market by Disease Diagnostics Type
- 5.2.1Global Gastrointestinal Disorders Market by Region
- 5.2.2Global Metabolic Diseases Market by Region
- 5.2.3Global Others Market by Region
5.3Global Research Application Market by Region

Chapter 6.Global Microbiome Diagnostics Market by Product

6.1Global Reagents & Kits Market by Region
6.2Global Instruments Market by Region

Chapter 7.Global Microbiome Diagnostics Market by Sample

7.1Global Fecal Market by Region
7.2Global Saliva Market by Region
7.3Global Skin Market by Region
7.4Global Others Market by Region

Chapter 8.Global Microbiome Diagnostics Market by Technology

8.1Global 16S rRNA Sequencing Market by Region
8.2Global Shot Gun Metagenomics Market by Region
8.3Global Metatranscriptomics Market by Region
8.4Global Others Market by Region

Chapter 9.Global Microbiome Diagnostics Market by End User

9.1Global Hospitals Market by Region
9.2Global Academic & Research Institutes Market by Region
9.3Global Biotechnology & Pharmaceutical Companies Market by Region

Chapter 10.Global Microbiome Diagnostics Market by Region

10.1North America Microbiome Diagnostics Market
- 10.1.1North America Microbiome Diagnostics Market by Application
  - 10.1.1.1North America Disease Diagnostics Market by Region
  - 10.1.1.2North America Microbiome Diagnostics Market by Disease Diagnostics Type
    - 10.1.1.2.1North America Gastrointestinal Disorders Market by Country
    - 10.1.1.2.2North America Metabolic Diseases Market by Country
    - 10.1.1.2.3North America Others Market by Country
  - 10.1.1.3North America Research Application Market by Region
- 10.1.2North America Microbiome Diagnostics Market by Product
  - 10.1.2.1North America Reagents & Kits Market by Country
  - 10.1.2.2North America Instruments Market by Country
- 10.1.3North America Microbiome Diagnostics Market by Sample
  - 10.1.3.1North America Fecal Market by Country
  - 10.1.3.2North America Saliva Market by Country
  - 10.1.3.3North America Skin Market by Country
  - 10.1.3.4North America Others Market by Country
- 10.1.4North America Microbiome Diagnostics Market by Technology
  - 10.1.4.1North America 16S rRNA Sequencing Market by Country
  - 10.1.4.2North America Shot Gun Metagenomics Market by Country
  - 10.1.4.3North America Metatranscriptomics Market by Country
  - 10.1.4.4North America Others Market by Country
- 10.1.5North America Microbiome Diagnostics Market by End User
  - 10.1.5.1North America Hospitals Market by Country
  - 10.1.5.2North America Academic & Research Institutes Market by Country
  - 10.1.5.3North America Biotechnology & Pharmaceutical Companies Market by Country
- 10.1.6North America Microbiome Diagnostics Market by Country
  - 10.1.6.1US Microbiome Diagnostics Market
    - 10.1.6.1.1US Microbiome Diagnostics Market by Application
    - 10.1.6.1.2US Microbiome Diagnostics Market by Product
    - 10.1.6.1.3US Microbiome Diagnostics Market by Sample
    - 10.1.6.1.4US Microbiome Diagnostics Market by Technology
    - 10.1.6.1.5US Microbiome Diagnostics Market by End User
  - 10.1.6.2Canada Microbiome Diagnostics Market
    - 10.1.6.2.1Canada Microbiome Diagnostics Market by Application
    - 10.1.6.2.2Canada Microbiome Diagnostics Market by Product
    - 10.1.6.2.3Canada Microbiome Diagnostics Market by Sample
    - 10.1.6.2.4Canada Microbiome Diagnostics Market by Technology
    - 10.1.6.2.5Canada Microbiome Diagnostics Market by End User
  - 10.1.6.3Mexico Microbiome Diagnostics Market
    - 10.1.6.3.1Mexico Microbiome Diagnostics Market by Application
    - 10.1.6.3.2Mexico Microbiome Diagnostics Market by Product
    - 10.1.6.3.3Mexico Microbiome Diagnostics Market by Sample
    - 10.1.6.3.4Mexico Microbiome Diagnostics Market by Technology
    - 10.1.6.3.5Mexico Microbiome Diagnostics Market by End User
  - 10.1.6.4Rest of North America Microbiome Diagnostics Market
    - 10.1.6.4.1Rest of North America Microbiome Diagnostics Market by Application
    - 10.1.6.4.2Rest of North America Microbiome Diagnostics Market by Product
    - 10.1.6.4.3Rest of North America Microbiome Diagnostics Market by Sample
    - 10.1.6.4.4Rest of North America Microbiome Diagnostics Market by Technology
    - 10.1.6.4.5Rest of North America Microbiome Diagnostics Market by End User
10.2Europe Microbiome Diagnostics Market
- 10.2.1Europe Microbiome Diagnostics Market by Application
  - 10.2.1.1Europe Disease Diagnostics Market by Country
  - 10.2.1.2Europe Microbiome Diagnostics Market by Disease Diagnostics Type
    - 10.2.1.2.1Europe Gastrointestinal Disorders Market by Country
    - 10.2.1.2.2Europe Metabolic Diseases Market by Country
    - 10.2.1.2.3Europe Others Market by Country
  - 10.2.1.3Europe Research Application Market by Country
- 10.2.2Europe Microbiome Diagnostics Market by Product
  - 10.2.2.1Europe Reagents & Kits Market by Country
  - 10.2.2.2Europe Instruments Market by Country
- 10.2.3Europe Microbiome Diagnostics Market by Sample
  - 10.2.3.1Europe Fecal Market by Country
  - 10.2.3.2Europe Saliva Market by Country
  - 10.2.3.3Europe Skin Market by Country
  - 10.2.3.4Europe Others Market by Country
- 10.2.4Europe Microbiome Diagnostics Market by Technology
  - 10.2.4.1Europe 16S rRNA Sequencing Market by Country
  - 10.2.4.2Europe Shot Gun Metagenomics Market by Country
  - 10.2.4.3Europe Metatranscriptomics Market by Country
  - 10.2.4.4Europe Others Market by Country
- 10.2.5Europe Microbiome Diagnostics Market by End User
  - 10.2.5.1Europe Hospitals Market by Country
  - 10.2.5.2Europe Academic & Research Institutes Market by Country
  - 10.2.5.3Europe Biotechnology & Pharmaceutical Companies Market by Country
- 10.2.6Europe Microbiome Diagnostics Market by Country
  - 10.2.6.1Germany Microbiome Diagnostics Market
    - 10.2.6.1.1Germany Microbiome Diagnostics Market by Application
    - 10.2.6.1.2Germany Microbiome Diagnostics Market by Product
    - 10.2.6.1.3Germany Microbiome Diagnostics Market by Sample
    - 10.2.6.1.4Germany Microbiome Diagnostics Market by Technology
    - 10.2.6.1.5Germany Microbiome Diagnostics Market by End User
  - 10.2.6.2UK Microbiome Diagnostics Market
    - 10.2.6.2.1UK Microbiome Diagnostics Market by Application
    - 10.2.6.2.2UK Microbiome Diagnostics Market by Product
    - 10.2.6.2.3UK Microbiome Diagnostics Market by Sample
    - 10.2.6.2.4UK Microbiome Diagnostics Market by Technology
    - 10.2.6.2.5UK Microbiome Diagnostics Market by End User
  - 10.2.6.3France Microbiome Diagnostics Market
    - 10.2.6.3.1France Microbiome Diagnostics Market by Application
    - 10.2.6.3.2France Microbiome Diagnostics Market by Product
    - 10.2.6.3.3France Microbiome Diagnostics Market by Sample
    - 10.2.6.3.4France Microbiome Diagnostics Market by Technology
    - 10.2.6.3.5France Microbiome Diagnostics Market by End User
  - 10.2.6.4Russia Microbiome Diagnostics Market
    - 10.2.6.4.1Russia Microbiome Diagnostics Market by Application
    - 10.2.6.4.2Russia Microbiome Diagnostics Market by Product
    - 10.2.6.4.3Russia Microbiome Diagnostics Market by Sample
    - 10.2.6.4.4Russia Microbiome Diagnostics Market by Technology
    - 10.2.6.4.5Russia Microbiome Diagnostics Market by End User
  - 10.2.6.5Spain Microbiome Diagnostics Market
    - 10.2.6.5.1Spain Microbiome Diagnostics Market by Application
    - 10.2.6.5.2Spain Microbiome Diagnostics Market by Product
    - 10.2.6.5.3Spain Microbiome Diagnostics Market by Sample
    - 10.2.6.5.4Spain Microbiome Diagnostics Market by Technology
    - 10.2.6.5.5Spain Microbiome Diagnostics Market by End User
  - 10.2.6.6Italy Microbiome Diagnostics Market
    - 10.2.6.6.1Italy Microbiome Diagnostics Market by Application
    - 10.2.6.6.2Italy Microbiome Diagnostics Market by Product
    - 10.2.6.6.3Italy Microbiome Diagnostics Market by Sample
    - 10.2.6.6.4Italy Microbiome Diagnostics Market by Technology
    - 10.2.6.6.5Italy Microbiome Diagnostics Market by End User
  - 10.2.6.7Rest of Europe Microbiome Diagnostics Market
    - 10.2.6.7.1Rest of Europe Microbiome Diagnostics Market by Application
    - 10.2.6.7.2Rest of Europe Microbiome Diagnostics Market by Product
    - 10.2.6.7.3Rest of Europe Microbiome Diagnostics Market by Sample
    - 10.2.6.7.4Rest of Europe Microbiome Diagnostics Market by Technology
    - 10.2.6.7.5Rest of Europe Microbiome Diagnostics Market by End User
10.3Asia Pacific Microbiome Diagnostics Market
- 10.3.1Asia Pacific Microbiome Diagnostics Market by Application
  - 10.3.1.1Asia Pacific Disease Diagnostics Market by Country
  - 10.3.1.2Asia Pacific Microbiome Diagnostics Market by Disease Diagnostics Type
    - 10.3.1.2.1Asia Pacific Gastrointestinal Disorders Market by Country
    - 10.3.1.2.2Asia Pacific Metabolic Diseases Market by Country
    - 10.3.1.2.3Asia Pacific Others Market by Country
  - 10.3.1.3Asia Pacific Research Application Market by Country
- 10.3.2Asia Pacific Microbiome Diagnostics Market by Product
  - 10.3.2.1Asia Pacific Reagents & Kits Market by Country
  - 10.3.2.2Asia Pacific Instruments Market by Country
- 10.3.3Asia Pacific Microbiome Diagnostics Market by Sample
  - 10.3.3.1Asia Pacific Fecal Market by Country
  - 10.3.3.2Asia Pacific Saliva Market by Country
  - 10.3.3.3Asia Pacific Skin Market by Country
  - 10.3.3.4Asia Pacific Others Market by Country
- 10.3.4Asia Pacific Microbiome Diagnostics Market by Technology
  - 10.3.4.1Asia Pacific 16S rRNA Sequencing Market by Country
  - 10.3.4.2Asia Pacific Shot Gun Metagenomics Market by Country
  - 10.3.4.3Asia Pacific Metatranscriptomics Market by Country
  - 10.3.4.4Asia Pacific Others Market by Country
- 10.3.5Asia Pacific Microbiome Diagnostics Market by End User
  - 10.3.5.1Asia Pacific Hospitals Market by Country
  - 10.3.5.2Asia Pacific Academic & Research Institutes Market by Country
  - 10.3.5.3Asia Pacific Biotechnology & Pharmaceutical Companies Market by Country
- 10.3.6Asia Pacific Microbiome Diagnostics Market by Country
  - 10.3.6.1China Microbiome Diagnostics Market
    - 10.3.6.1.1China Microbiome Diagnostics Market by Application
    - 10.3.6.1.2China Microbiome Diagnostics Market by Product
    - 10.3.6.1.3China Microbiome Diagnostics Market by Sample
    - 10.3.6.1.4China Microbiome Diagnostics Market by Technology
    - 10.3.6.1.5China Microbiome Diagnostics Market by End User
  - 10.3.6.2Japan Microbiome Diagnostics Market
    - 10.3.6.2.1Japan Microbiome Diagnostics Market by Application
    - 10.3.6.2.2Japan Microbiome Diagnostics Market by Product
    - 10.3.6.2.3Japan Microbiome Diagnostics Market by Sample
    - 10.3.6.2.4Japan Microbiome Diagnostics Market by Technology
    - 10.3.6.2.5Japan Microbiome Diagnostics Market by End User
  - 10.3.6.3India Microbiome Diagnostics Market
    - 10.3.6.3.1India Microbiome Diagnostics Market by Application
    - 10.3.6.3.2India Microbiome Diagnostics Market by Product
    - 10.3.6.3.3India Microbiome Diagnostics Market by Sample
    - 10.3.6.3.4India Microbiome Diagnostics Market by Technology
    - 10.3.6.3.5India Microbiome Diagnostics Market by End User
  - 10.3.6.4South Korea Microbiome Diagnostics Market
    - 10.3.6.4.1South Korea Microbiome Diagnostics Market by Application
    - 10.3.6.4.2South Korea Microbiome Diagnostics Market by Product
    - 10.3.6.4.3South Korea Microbiome Diagnostics Market by Sample
    - 10.3.6.4.4South Korea Microbiome Diagnostics Market by Technology
    - 10.3.6.4.5South Korea Microbiome Diagnostics Market by End User
  - 10.3.6.5Australia Microbiome Diagnostics Market
    - 10.3.6.5.1Australia Microbiome Diagnostics Market by Application
    - 10.3.6.5.2Australia Microbiome Diagnostics Market by Product
    - 10.3.6.5.3Australia Microbiome Diagnostics Market by Sample
    - 10.3.6.5.4Australia Microbiome Diagnostics Market by Technology
    - 10.3.6.5.5Australia Microbiome Diagnostics Market by End User
  - 10.3.6.6Malaysia Microbiome Diagnostics Market
    - 10.3.6.6.1Malaysia Microbiome Diagnostics Market by Application
    - 10.3.6.6.2Malaysia Microbiome Diagnostics Market by Product
    - 10.3.6.6.3Malaysia Microbiome Diagnostics Market by Sample
    - 10.3.6.6.4Malaysia Microbiome Diagnostics Market by Technology
    - 10.3.6.6.5Malaysia Microbiome Diagnostics Market by End User
  - 10.3.6.7Rest of Asia Pacific Microbiome Diagnostics Market
    - 10.3.6.7.1Rest of Asia Pacific Microbiome Diagnostics Market by Application
    - 10.3.6.7.2Rest of Asia Pacific Microbiome Diagnostics Market by Product
    - 10.3.6.7.3Rest of Asia Pacific Microbiome Diagnostics Market by Sample
    - 10.3.6.7.4Rest of Asia Pacific Microbiome Diagnostics Market by Technology
    - 10.3.6.7.5Rest of Asia Pacific Microbiome Diagnostics Market by End User
10.4LAMEA Microbiome Diagnostics Market
- 10.4.1LAMEA Microbiome Diagnostics Market by Application
  - 10.4.1.1LAMEA Disease Diagnostics Market by Country
  - 10.4.1.2LAMEA Microbiome Diagnostics Market by Disease Diagnostics Type
    - 10.4.1.2.1LAMEA Gastrointestinal Disorders Market by Country
    - 10.4.1.2.2LAMEA Metabolic Diseases Market by Country
    - 10.4.1.2.3LAMEA Others Market by Country
  - 10.4.1.3LAMEA Research Application Market by Country
- 10.4.2LAMEA Microbiome Diagnostics Market by Product
  - 10.4.2.1LAMEA Reagents & Kits Market by Country
  - 10.4.2.2LAMEA Instruments Market by Country
- 10.4.3LAMEA Microbiome Diagnostics Market by Sample
  - 10.4.3.1LAMEA Fecal Market by Country
  - 10.4.3.2LAMEA Saliva Market by Country
  - 10.4.3.3LAMEA Skin Market by Country
  - 10.4.3.4LAMEA Others Market by Country
- 10.4.4LAMEA Microbiome Diagnostics Market by Technology
  - 10.4.4.1LAMEA 16S rRNA Sequencing Market by Country
  - 10.4.4.2LAMEA Shot Gun Metagenomics Market by Country
  - 10.4.4.3LAMEA Metatranscriptomics Market by Country
  - 10.4.4.4LAMEA Others Market by Country
- 10.4.5LAMEA Microbiome Diagnostics Market by End User
  - 10.4.5.1LAMEA Hospitals Market by Country
  - 10.4.5.2LAMEA Academic & Research Institutes Market by Country
  - 10.4.5.3LAMEA Biotechnology & Pharmaceutical Companies Market by Country
- 10.4.6LAMEA Microbiome Diagnostics Market by Country
  - 10.4.6.1Brazil Microbiome Diagnostics Market
    - 10.4.6.1.1Brazil Microbiome Diagnostics Market by Application
    - 10.4.6.1.2Brazil Microbiome Diagnostics Market by Product
    - 10.4.6.1.3Brazil Microbiome Diagnostics Market by Sample
    - 10.4.6.1.4Brazil Microbiome Diagnostics Market by Technology
    - 10.4.6.1.5Brazil Microbiome Diagnostics Market by End User
  - 10.4.6.2Argentina Microbiome Diagnostics Market
    - 10.4.6.2.1Argentina Microbiome Diagnostics Market by Application
    - 10.4.6.2.2Argentina Microbiome Diagnostics Market by Product
    - 10.4.6.2.3Argentina Microbiome Diagnostics Market by Sample
    - 10.4.6.2.4Argentina Microbiome Diagnostics Market by Technology
    - 10.4.6.2.5Argentina Microbiome Diagnostics Market by End User
  - 10.4.6.3UAE Microbiome Diagnostics Market
    - 10.4.6.3.1UAE Microbiome Diagnostics Market by Application
    - 10.4.6.3.2UAE Microbiome Diagnostics Market by Product
    - 10.4.6.3.3UAE Microbiome Diagnostics Market by Sample
    - 10.4.6.3.4UAE Microbiome Diagnostics Market by Technology
    - 10.4.6.3.5UAE Microbiome Diagnostics Market by End User
  - 10.4.6.4Saudi Arabia Microbiome Diagnostics Market
    - 10.4.6.4.1Saudi Arabia Microbiome Diagnostics Market by Application
    - 10.4.6.4.2Saudi Arabia Microbiome Diagnostics Market by Product
    - 10.4.6.4.3Saudi Arabia Microbiome Diagnostics Market by Sample
    - 10.4.6.4.4Saudi Arabia Microbiome Diagnostics Market by Technology
    - 10.4.6.4.5Saudi Arabia Microbiome Diagnostics Market by End User
  - 10.4.6.5South Africa Microbiome Diagnostics Market
    - 10.4.6.5.1South Africa Microbiome Diagnostics Market by Application
    - 10.4.6.5.2South Africa Microbiome Diagnostics Market by Product
    - 10.4.6.5.3South Africa Microbiome Diagnostics Market by Sample
    - 10.4.6.5.4South Africa Microbiome Diagnostics Market by Technology
    - 10.4.6.5.5South Africa Microbiome Diagnostics Market by End User
  - 10.4.6.6Nigeria Microbiome Diagnostics Market
    - 10.4.6.6.1Nigeria Microbiome Diagnostics Market by Application
    - 10.4.6.6.2Nigeria Microbiome Diagnostics Market by Product
    - 10.4.6.6.3Nigeria Microbiome Diagnostics Market by Sample
    - 10.4.6.6.4Nigeria Microbiome Diagnostics Market by Technology
    - 10.4.6.6.5Nigeria Microbiome Diagnostics Market by End User
  - 10.4.6.7Rest of LAMEA Microbiome Diagnostics Market
    - 10.4.6.7.1Rest of LAMEA Microbiome Diagnostics Market by Application
    - 10.4.6.7.2Rest of LAMEA Microbiome Diagnostics Market by Product
    - 10.4.6.7.3Rest of LAMEA Microbiome Diagnostics Market by Sample
    - 10.4.6.7.4Rest of LAMEA Microbiome Diagnostics Market by Technology
    - 10.4.6.7.5Rest of LAMEA Microbiome Diagnostics Market by End User

Chapter 11.Company Profiles

11.1Illumina, Inc.
- 11.1.1Company Overview
- 11.1.2Financial Analysis
- 11.1.3Regional Analysis
- 11.1.4Research & Development Expense
- 11.1.5Recent strategies and developments:
  - 11.1.5.1Partnerships, Collaborations, and Agreements:
- 11.1.6SWOT Analysis
11.2Becton, Dickinson, and Company
- 11.2.1Company Overview
- 11.2.2Financial Analysis
- 11.2.3Segmental and Regional Analysis
- 11.2.4Research & Development Expense
- 11.2.5Recent strategies and developments:
  - 11.2.5.1Product Launches and Product Expansions:
  - 11.2.5.2Trails and Approvals:
- 11.2.6SWOT Analysis
11.3Genetic Analysis AS
- 11.3.1Company Overview
- 11.3.2Financial Analysis
- 11.3.3Regional Analysis
- 11.3.4Recent strategies and developments:
  - 11.3.4.1Partnerships, Collaborations, and Agreements:
11.4Microba Life Sciences Limited
- 11.4.1Company Overview
- 11.4.2Financial Analysis
- 11.4.3Regional Analysis
- 11.4.4Research & Development Expenses
- 11.4.5Recent strategies and developments:
  - 11.4.5.1Partnerships, Collaborations, and Agreements:
  - 11.4.5.2Product Launches and Product Expansions:
11.5BioMe Oxford Ltd
- 11.5.1Company Overview
- 11.5.2Recent strategies and developments:
  - 11.5.2.1Partnerships, Collaborations, and Agreements:
11.6Viome Life Sciences, Inc.
- 11.6.1Company Overview
- 11.6.2Recent strategies and developments:
  - 11.6.2.1Product Launches and Product Expansions:
  - 11.6.2.2Acquisition and Mergers:
11.7GoodGut S.L.U. (HIPRA, S.A.)
- 11.7.1Company Overview
11.8Sun Genomics
- 11.8.1Company Overview
11.9Origin Sciences Limited
- 11.9.1Company Overview
11.10.Decode Age
- 11.10.1Company Overview

한글목차

목차

제1장 시장 범위와 조사 방법

제2장 시장 요람

제3장 시장 개요

제4장 마이크로바이옴 진단 시장에서 전개되는 전략

제5장 세계의 마이크로바이옴 진단 시장 : 용도별

제6장 세계의 마이크로바이옴 진단 시장 : 제품별

제7장 세계의 마이크로바이옴 진단 시장 : 샘플별

제8장 세계의 마이크로바이옴 진단 시장 : 기술별

제9장 세계의 마이크로바이옴 진단 시장 : 최종사용자별

제10장 세계의 마이크로바이옴 진단 시장 : 지역별